Biocryst Pharma Inc (BCRX) Stock Price, Quote & News

Company Profile

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phas...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 919 859 1302

Fax: 919 859 1314

Website: www.biocryst.com

Address:

4505 Emperor Boulevard, Suite 200, Durham, United States

MattressMonkey007 Aug. 23 at 5:42 PM

$BCRX … Sometime a nod is just as good as a wink to blind men:

0 · Reply

guspug1115 Aug. 23 at 4:16 PM

$BCRX Speculations of a buy out, tutes holding price stagnant for long periods to eventually flush out retail, bio sector not in favor as of now, schizophrenic market ( depending on who is talking that day or week ), earnings, debt etc. All talked about on this thread. What about the possibility of the company going private ? Not saying that’s happening so please don’t hate on me just asking what I believe is a serious ? Any thoughts good or bad. Thanks and have a great weekend.

1 · Reply

Ttubular Aug. 23 at 2:17 PM

$BCRX snob_order posted some really nice info on BCRX. With all the info we have of BCRX cleaning up the company who thinks they did it for a BO? If so when do u all think it would happen and price? I’m thinking 1st half of next year for $20

2 · Reply

Surgemono Aug. 23 at 2:05 PM

$BCRX reading all the great posts Thank You @SNOB_ORDER (Gratzie) this place is a ticking 💣. Happy to be here.

0 · Reply

Stonehands Aug. 23 at 1:19 PM

$BCRX I think the BCRX longs here on ST must hold all of the few shares not owned by tutes. Make something happen. Biowar again? Lol

1 · Reply

SNOB_ORDER Aug. 23 at 1:10 PM

$BCRX Bnp Paribas Arbitrage, Sa reports 1,059.67% increase in ownership of BCRX / BioCryst Pharmaceuticals, Inc. On August 14, 2025 - Bnp Paribas Arbitrage, Sa filed a 13F-HR form disclosing ownership of 1,456,857 shares of BioCryst Pharmaceuticals, Inc. (US:BCRX) valued at $13,053,439 USD as of June 30, 2025. The entity filed a previous 13F-HR on May 14, 2025 disclosing 125,627 shares of BioCryst Pharmaceuticals, Inc.. This represents a change in shares of 1,059.67% during the quarter. The current value of the position is $12,470,696 USD.

4 · Reply

SNOB_ORDER Aug. 23 at 1:09 PM

$BCRX Goldman Sachs Group Inc ownership in BCRX / BioCryst Pharmaceuticals, Inc. On August 14, 2025 - Goldman Sachs Group Inc filed a 13F-HR form disclosing ownership of 3,523,917 shares of BioCryst Pharmaceuticals, Inc. (US:BCRX) valued at $31,574,296 USD as of June 30, 2025. The entity filed a previous 13F-HR/A on June 27, 2025 disclosing 1,931,934 shares of BioCryst Pharmaceuticals, Inc.. This represents a change in shares of 82.40% during the quarter. The current value of the position is $30,164,730 USD. Goldman Sachs Group Inc has a history of taking positions in derivatives of the underlying security (BCRX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

0 · Reply

SNOB_ORDER Aug. 23 at 1:07 PM

$BCRX D. E. Shaw & Co., Inc. reports 176.22% increase in ownership of BCRX / BioCryst Pharmaceuticals, Inc. On August 14, 2025 - D. E. Shaw & Co., Inc. filed a 13F-HR form disclosing ownership of 4,389,477 shares of BioCryst Pharmaceuticals, Inc. (US:BCRX) valued at $39,329,714 USD as of June 30, 2025. The entity filed a previous 13F-HR on May 15, 2025 disclosing 1,589,112 shares of BioCryst Pharmaceuticals, Inc.. This represents a change in shares of 176.22% during the quarter. The current value of the position is $37,573,923 USD.

0 · Reply

SNOB_ORDER Aug. 23 at 1:06 PM

$BCRX Two Sigma Investments, Lp reports 109.64% increase in ownership of BCRX / BioCryst Pharmaceuticals, Inc. On August 14, 2025 - Two Sigma Investments, Lp filed a 13F-HR form disclosing ownership of 4,288,223 shares of BioCryst Pharmaceuticals, Inc. (US:BCRX) valued at $38,422,478 USD as of June 30, 2025. The entity filed a previous 13F-HR on May 15, 2025 disclosing 2,045,535 shares of BioCryst Pharmaceuticals, Inc.. This represents a change in shares of 109.64% during the quarter. The current value of the position is $36,707,189 USD.

1 · Reply

SNOB_ORDER Aug. 23 at 1:03 PM

$BCRX Bank Of America Corp /de/ ownership in BCRX / BioCryst Pharmaceuticals, Inc. On August 14, 2025 - Bank Of America Corp /de/ filed a 13F-HR form disclosing ownership of 2,841,155 shares of BioCryst Pharmaceuticals, Inc. (US:BCRX) valued at $25,456,749 USD as of June 30, 2025. The entity filed a previous 13F-HR on May 15, 2025 disclosing 1,435,657 shares of BioCryst Pharmaceuticals, Inc.. This represents a change in shares of 97.90% during the quarter. The current value of the position is $24,320,287 USD. Bank Of America Corp /de/ has a history of taking positions in derivatives of the underlying security (BCRX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

1 · Reply

BioCryst to Present at Upcoming Investor Conference

Aug 11, 2025, 7:00 AM EDT - 12 days ago

BioCryst Announces Departure of Dr. Helen Thackray

Aug 6, 2025, 7:00 AM EDT - 17 days ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 4, 2025, 11:38 AM EDT - 19 days ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 7:00 AM EDT - 19 days ago

BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 7:00 AM EDT - 23 days ago

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

Jul 21, 2025, 7:00 AM EDT - 4 weeks ago

BioCryst to Report Second Quarter 2025 Financial Results on August 4

Jul 9, 2025, 7:00 AM EDT - 6 weeks ago

BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit

Jul 7, 2025, 7:00 AM EDT - 6 weeks ago

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

Jun 27, 2025, 7:00 AM EDT - 2 months ago

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

Jun 16, 2025, 7:00 AM EDT - 2 months ago

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

Jun 13, 2025, 7:00 AM EDT - 2 months ago

ORLADEYO® (berotralstat) Approved in Colombia

Jun 6, 2025, 7:00 AM EDT - 2 months ago

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

Jun 2, 2025, 7:00 AM EDT - 2 months ago

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

May 30, 2025, 7:00 AM EDT - 3 months ago

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

May 27, 2025, 7:00 AM EDT - 3 months ago

BioCryst to Present at Upcoming Investor Conferences

May 16, 2025, 7:00 AM EDT - 3 months ago

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

May 14, 2025, 7:00 AM EDT - 3 months ago

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

May 5, 2025, 5:29 PM EDT - 3 months ago

BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors

May 5, 2025, 2:05 PM EDT - 3 months ago

BioCryst: Strong Opportunity For A Double With A Proven Therapy

May 5, 2025, 12:54 PM EDT - 3 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2025 Earnings Call Transcript

May 5, 2025, 7:00 AM EDT - 3 months ago

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 7:00 AM EDT - 4 months ago

BioCryst Appoints Steve Frank to Board of Directors

Apr 21, 2025, 7:00 AM EDT - 4 months ago

BioCryst to Report First Quarter 2025 Financial Results on May 5

Feb 26, 2025, 9:09 AM EST - 6 months ago

BioCryst: Orladeyo's Expansion Is Just Getting Started

Feb 26, 2025, 7:45 AM EST - 6 months ago

BioCryst: Hold Steady As Orladeyo Builds, But Competition Heats Up

Feb 25, 2025, 6:24 PM EST - 6 months ago

BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical

Feb 24, 2025, 12:17 PM EST - 6 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 11:49 AM EST - 6 months ago

BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings

Feb 24, 2025, 7:00 AM EST - 6 months ago

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

Feb 24, 2025, 6:00 AM EST - 6 months ago

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to

Feb 12, 2025, 7:00 AM EST - 6 months ago

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

Feb 10, 2025, 8:30 AM EST - 6 months ago

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

Feb 10, 2025, 7:00 AM EST - 6 months ago

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

Jan 10, 2025, 7:00 AM EST - 8 months ago

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

Jan 7, 2025, 7:00 AM EST - 8 months ago

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 1:47 PM EST - 9 months ago

BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy

Nov 18, 2024, 2:00 AM EST - 9 months ago

BioCryst Launches ORLADEYO® (berotralstat) in Ireland

Nov 4, 2024, 11:00 AM EST - 10 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2024 Earnings Call Transcript

Oct 21, 2024, 7:00 AM EDT - 10 months ago

BioCryst to Report Third Quarter 2024 Financial Results on November 4

Oct 14, 2024, 7:00 AM EDT - 11 months ago

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)

Oct 2, 2024, 7:00 AM EDT - 11 months ago

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome

Sep 30, 2024, 7:00 AM EDT - 11 months ago

U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile

Sep 17, 2024, 7:00 AM EDT - 1 year ago

BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks

Sep 6, 2024, 2:00 AM EDT - 1 year ago

BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium

Aug 5, 2024, 11:44 AM EDT - 1 year ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 7:00 AM EDT - 1 year ago

BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 22, 2024, 7:00 AM EDT - 1 year ago

BioCryst to Report Second Quarter 2024 Financial Results on August 5

Jul 21, 2024, 7:30 AM EDT - 1 year ago

Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects

Jul 9, 2024, 7:00 AM EDT - 1 year ago

ORLADEYO® (berotralstat) Approved in Peru

MattressMonkey007 Aug. 23 at 5:42 PM

$BCRX … Sometime a nod is just as good as a wink to blind men:

0 · Reply

guspug1115 Aug. 23 at 4:16 PM

1 · Reply

Ttubular Aug. 23 at 2:17 PM

2 · Reply

Surgemono Aug. 23 at 2:05 PM

$BCRX reading all the great posts Thank You @SNOB_ORDER (Gratzie) this place is a ticking 💣. Happy to be here.

0 · Reply

Stonehands Aug. 23 at 1:19 PM

$BCRX I think the BCRX longs here on ST must hold all of the few shares not owned by tutes. Make something happen. Biowar again? Lol

1 · Reply

SNOB_ORDER Aug. 23 at 1:10 PM

4 · Reply

SNOB_ORDER Aug. 23 at 1:09 PM

0 · Reply

SNOB_ORDER Aug. 23 at 1:07 PM

0 · Reply

SNOB_ORDER Aug. 23 at 1:06 PM

1 · Reply

SNOB_ORDER Aug. 23 at 1:03 PM

1 · Reply

SNOB_ORDER Aug. 23 at 1:00 PM

$BCRX Morgan Stanley reports 131.96% increase in ownership of BCRX / BioCryst Pharmaceuticals, Inc. On August 15, 2025 - Morgan Stanley filed a 13F-HR form disclosing ownership of 5,329,679 shares of BioCryst Pharmaceuticals, Inc. (US:BCRX) valued at $47,753,924 USD as of June 30, 2025. The entity filed a previous 13F-HR on May 15, 2025 disclosing 2,297,674 shares of BioCryst Pharmaceuticals, Inc.. This represents a change in shares of 131.96% during the quarter. The current value of the position is $45,622,052 USD.

1 · Reply

TheVulcanDevilWhale Aug. 23 at 12:55 PM

$BCRX 9.17 🖖🏽

2 · Reply

fatpie68 Aug. 23 at 12:51 PM

$BCRX increased Institutional Ownership by 5.1% between August 15-22. Also, the downtrend officially reversed on the weekly chart.

0 · Reply

SNOB_ORDER Aug. 23 at 12:28 PM

$BCRX BCRX at glance: Q2 2025 ORLADEYO net revenue of $156.8 million (+45 % y/y) Q2 2025 operating profit of $29.8 million (+239 % y/y); non-GAAP operating profit of $57.0 million (+160 % y/y) Makes additional $50 million paydown of term debt and plans to retire all remaining term debt with proceeds of sale of European ORLADEYO business, $264 mil - ($125 million in Pharmakon prepayments made in 2025) New patient prescriptions in the 2Q were the highest ever in a quarter, beating those in the first quarter of the launch by over 10%. The number of new prescribers of ORLADEYO in the U.S. in the 2Q increased to 69, up from 59 in the 1Q. Patient discontinuations in the U.S. were lower in the 1H/25 than in the 1H/24, despite the larger base of patients taking ORLADEYO on Oct, European deal closing on Nov, 3Q data on 12th Dec, PDUFA Orla P. Orladeyo, 2nd drugs more sold in the world, is growing more than leader Takhzyro New CFO, President and CEO Institutional Ownership 95.84% (Nasdaq source) .....

2 · Reply

MetaverseMogul Aug. 23 at 7:08 AM

$BCRX BioCryst Pharmaceuticals Inc has commercial products but faces competition and cash burn

1 · Reply

Paulzk Aug. 23 at 5:21 AM

$BCRX Is Natural Gas signaling a slowing economy. Hitting new lows here???

1 · Reply

P119 Aug. 22 at 9:07 PM

$BCRX missing old $BCRX Friday’s

0 · Reply

tylax30 Aug. 22 at 8:08 PM

$BCRX just a Friday reminder.

2 · Reply

YerbMe Aug. 22 at 7:14 PM

$BCRX

0 · Reply

Pharm_Hand Aug. 22 at 6:29 PM

$BCRX There's not much fuglier than BCRX's 3 month chart following the May hype

4 · Reply

doublebtx Aug. 22 at 5:46 PM

$BCRX It's a really slow day today, so I decided to take a look at AUPH. Admittedly this is just very high level glance and I know nothing about the company itself, but I have seen people say it is similar in many ways to BCRX. They just upped their guidance to 260-270M this year as part of Q2 reporting (which was a beat similar to here but they are up 33% since then while we are...not), and are at a 1.6B MC. That is about 6x revenue, which falls into what I would consider the "normal range" of 5-7x for bios. Contrast that to here, where they will do 600M in revenue and are trading at a 1.8B MC, a mere 3x revenue. Yet something else that points to this should be at $15-16, not $8-9.

3 · Reply

Cello69 Aug. 22 at 5:14 PM

$BCRX They just won't let this run. Sucks

1 · Reply

Market Cap	1.76B
Revenue (ttm)	450.71M
Net Income (ttm)	-88.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	93.11
Profit Margin	-19.72%
Debt to Equity Ratio	-1.72

Volume	2,200,400
Avg Vol	3,330,180
Day's Range	N/A - N/A
Shares Out	209.92M
Stochastic %K	83%
Beta	1.10
Analysts	Strong Sell
Price Target	$16.82